CONFLICT OF INTEREST STATEMENT
DER
MJK reports personal fees as a speaker or consultant from Arvelle, BIAL, Eisai, GW Pharmaceuticals, Novartis, and UCB Pharma. ET reports personal fees from EVER Pharma, Marinus, Arvelle, Angelini, Argenx, Medtronic, Bial‐Portela & Cª, NewBridge, GL Pharma, GlaxoSmithKline, Boehringer Ingelheim, LivaNova, Eisai, UCB, Biogen, Sanofi, Jazz Pharmaceuticals, and Actavis. His institution received grants from Biogen, UCB Pharma, Eisai, Red Bull, Merck, Bayer, the European Union, FWF Osterreichischer Fond zur Wissenschaftsforderung, Bundesministerium für Wissenschaft und Forschung, and Jubiläumsfond der Österreichischen Nationalbank. YHM has no conflicts of interest to disclose. CB reports personal fees as a speaker or consultant from Angelini, BIAL, Medtronic, and Eisai. SK reports personal fees as a speaker or consultant from Angelini, Bial, Desitin, Eisai, Merck Serono, Precisis, UCB Pharma, and Zogenix. GLG reports personal fees from Angelini, Neuraxpharm, and Idorsia, and institutional support from Roche and Penta. JMS reports personal fees as a consultant/advisor from Arvelle Therapeutics, Angelini, BIAL, Eisai, Jazz Pharmaceuticals, Sanofi, UCB Pharma; and speaker honoraria from Arvelle Therapeutics, Angelini, BIAL, Eisai, Sanofi, UCB Pharma. JZ reports speaker honoraria for unbranded educations from Eisai and UCB, and as an employee of Sahlgrenska University (no personal compensation) being an investigator/subinvestigator in clinical trials sponsored by UCB, GW Pharma, Bial, and SK Life Science. LMM is an employee of Bial – Portela & Cª, S.A. AP was an employee of Bial – Portela & Cª, S.A. at the time this study was implemented but is currently employed at BlueClinical, Portugal. JM is an employee of Bial – Portela & Cª, S.A. PS is an employee of Bial – Portela & Cª, S.A. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.